Patents by Inventor Julianne Smith
Julianne Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11944643Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: GrantFiled: March 30, 2018Date of Patent: April 2, 2024Assignee: CELLECTIS SAInventors: Julianne Smith, Philippe Duchateau, Murielle Derrien
-
Patent number: 11891614Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 17, 2020Date of Patent: February 6, 2024Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20230201260Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: November 17, 2022Publication date: June 29, 2023Applicant: CELLECTISInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11603539Abstract: Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2013Date of Patent: March 14, 2023Assignee: CELLECTISInventors: Roman Galetto, Agnès Gouble, Stéphanie Grosse, Cécile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20230056268Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: April 8, 2022Publication date: February 23, 2023Applicant: CELLECTISInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20230050345Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: April 7, 2022Publication date: February 16, 2023Applicant: CELLECTISInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cécile SCHIFFER-MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20220348955Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: June 24, 2022Publication date: November 3, 2022Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11414674Abstract: A method of expanding deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: March 22, 2019Date of Patent: August 16, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Publication number: 20220227874Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.Type: ApplicationFiled: January 27, 2022Publication date: July 21, 2022Inventors: Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu
-
Publication number: 20220177914Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: February 17, 2022Publication date: June 9, 2022Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Patent number: 11311575Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2014Date of Patent: April 26, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 11304975Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: May 13, 2014Date of Patent: April 19, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 11274316Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: GrantFiled: March 11, 2021Date of Patent: March 15, 2022Assignee: CELLECTISInventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cecile Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
-
Patent number: 11267892Abstract: The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for using these CARs and engineered immune cells for the treatment of EGFRvIII-mediated pathologies, including cancers such as glioblastoma.Type: GrantFiled: January 23, 2019Date of Patent: March 8, 2022Assignee: Pfizer Inc.Inventors: Oi Kwan Wong, Joyce Ching Chou, Mathilde Brunnhilde Dusseaux, Julianne Smith, Barbra Johnson Sasu
-
Patent number: 11077144Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: November 16, 2020Date of Patent: August 3, 2021Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Publication number: 20210220405Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.Type: ApplicationFiled: March 11, 2021Publication date: July 22, 2021Applicant: CellectisInventors: Roman GALETTO, Agnes GOUBLE, Stephanie GROSSE, Cecile MANNIOUI, Laurent POIROT, Andrew SCHARENBERG, Julianne SMITH
-
Publication number: 20210161954Abstract: The present invention relates to an engineered immune cell endowed with a new CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect said immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.Type: ApplicationFiled: March 30, 2018Publication date: June 3, 2021Inventors: Julianne Smith, Philippe Duchateau, Murielle Derrien
-
Patent number: 11014989Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.Type: GrantFiled: January 25, 2016Date of Patent: May 25, 2021Assignee: CellectisInventors: Julianne Smith, Julien Valton, Alexandre Juillerat, Philippe Duchateau, Barbra Johnson Sasu, Arvind Rajpal
-
Patent number: 11007224Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: GrantFiled: November 16, 2020Date of Patent: May 18, 2021Assignee: CellectisInventors: Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
-
Publication number: 20210060079Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.Type: ApplicationFiled: November 16, 2020Publication date: March 4, 2021Inventors: Roman GALETTO, Julianne SMITH, Andrew SCHARENBERG, Cécile SCHIFFER-MANNIOUI